Public Employees Retirement System of Ohio Invests $2.25 Million in Omnicell, Inc. $OMCL

Public Employees Retirement System of Ohio bought a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 54,273 shares of the company’s stock, valued at approximately $2,253,000. Public Employees Retirement System of Ohio owned 0.12% of Omnicell as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Raymond James Financial Inc. bought a new position in Omnicell in the 2nd quarter worth approximately $26,000. Versant Capital Management Inc boosted its position in shares of Omnicell by 38.7% in the second quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock valued at $44,000 after acquiring an additional 294 shares during the period. Clearstead Advisors LLC boosted its position in shares of Omnicell by 12,180.0% in the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after acquiring an additional 1,218 shares during the period. Kemnay Advisory Services Inc. acquired a new stake in shares of Omnicell in the fourth quarter worth $58,000. Finally, Parkside Financial Bank & Trust grew its stake in shares of Omnicell by 1,708.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock worth $61,000 after acquiring an additional 1,264 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on OMCL shares. Zacks Research cut shares of Omnicell from a “hold” rating to a “strong sell” rating in a research note on Friday, August 7th. Piper Sandler restated an “overweight” rating and issued a $45.00 price target (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. Weiss Ratings upgraded shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 18th. Wells Fargo & Company cut their price objective on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Finally, Wall Street Zen upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $57.86.

Omnicell Stock Down 1.3%

OMCL opened at $34.37 on Friday. Omnicell, Inc. has a fifty-two week low of $29.06 and a fifty-two week high of $55.00. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43. The firm’s fifty day moving average price is $39.34 and its two-hundred day moving average price is $39.24. The company has a market capitalization of $1.56 billion, a P/E ratio of 40.92, a P/E/G ratio of 0.86 and a beta of 0.97.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.47. The company had revenue of $312.21 million during the quarter, compared to analysts’ expectations of $310.21 million. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The business’s revenue was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. On average, analysts anticipate that Omnicell, Inc. will post 1.41 EPS for the current year.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.